Related Experiment Videos
The complement system in systemic lupus erythematosus
Insights
Systemic lupus erythematosus (SLE) involves genetics and autoimmunity. Complement deficiencies, both hereditary and acquired, impact SLE pathogenesis and diagnosis, though new tests need validation.
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) etiology is multifactorial, influenced by genetics and autoimmunity.
- Hereditary complement deficiencies increase SLE risk and inform pathogenetic understanding.
- Acquired complement deficiency is common in SLE patients.
Discussion:
- Complement plays dual roles in SLE, offering protection while contributing to tissue damage.
- Measuring classical pathway complement components aids SLE diagnosis and monitoring of immune complex diseases like glomerulonephritis.
Key Insights:
- Genetic factors significantly impact SLE development.
- Complement system abnormalities are crucial in SLE pathogenesis.
- Classical pathway complement component measurement is vital for clinical management.
Outlook:
- Further research is needed to establish the clinical utility of novel complement activation assays.
- Understanding complement's role may lead to targeted SLE therapies.
Abstract:
The etiology of SLE is multifactorial with an important genetic impact. Several genes involved in control of autoimmunity and inflammation appear to be important. Hereditary complement deficiency states are associated with increased risk of SLE, but contribute only marginally to the incidence of SLE in the population. However, these conditions have contributed considerably to the knowledge of pathogenetic mechanisms in this disease. Furthermore, acquired complement deficiency is a common finding in SLE. Complement has important protective functions but also contributes to tissue damage. Measurement of classical pathway complement components is important in the diagnosis of SLE and for monitoring of immune complex mediated manifestations, especially proliferative glomerulonephritis. New complement activation tests, although promising in studies of selected patient groups, have not yet been proven to be of clinical value.